2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1492

Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1556

Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1405

Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1132

Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1584

Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1197

Factors Associated with Clinical Disease Activity Index Adoption at an Academic Rheumatology Practice

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1618

Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1673

Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1150

Factors Associated with Participation in Rheumatic Disease-Related Research Among Underrepresented Populations: A Systematic Review

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1614

Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1122

Factors Impacting Referral of Juvenile Idiopathic Arthritis Patients to a Tertiary Level Pediatric Rheumatology Center in North India

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1578

Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1474

Factors Influencing the ESSPRI Index in Primary Sjögren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1337

Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 983

Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection

RA – Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].